^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GCN2 activator

    Related drugs:
    21d
    Advances in Prostate Cancer Treatment: Exploring Molecular Targets and New Strategies in Castration-Resistant Disease. (PubMed, Cureus)
    Key developments include next-generation AR pathway inhibitors, such as darolutamide, with improved safety profiles; PARP inhibitors for patients with DNA repair gene mutations; and PSMA-targeted radioligand therapy. The therapeutic landscape is also expanding to include novel targets such as the heat shock response, with HSF1 inhibitors like NXP800 in clinical trials for treatment-refractory disease. By targeting this molecular heterogeneity, ongoing research aims to deliver more effective, personalized treatments to improve survival and quality of life for men with advanced prostate cancer.
    Review • Journal • PARP Biomarker
    |
    AR (Androgen receptor) • HSF1 (Heat Shock Transcription Factor 1)
    |
    Nubeqa (darolutamide) • NXP800
    1m
    NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    NXP800
    3ms
    Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (clinicaltrials.gov)
    P1, N=60, Recruiting, Deciphera Pharmaceuticals, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    NXP800-101: A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Nuvectis Pharma, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ARID1A (AT-rich interaction domain 1A) • BRCA (Breast cancer early onset)
    |
    ARID1A mutation • BRCA mutation
    |
    NXP800
    7ms
    Study of DCC-2812 in Participants With Advanced Genitourinary Cancers (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    11ms
    NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth. (PubMed, Clin Cancer Res)
    Overall, NXP800 has anti-tumor activity against treatment-resistant PCa models, including molecular subtypes with limited treatment options, supporting its consideration for PCa-specific clinical development.
    Journal
    |
    HSF1 (Heat Shock Transcription Factor 1)
    |
    NXP800
    1year
    NXP800-101: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (clinicaltrials.gov)
    P1, N=61, Recruiting, Nuvectis Pharma, Inc. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    ARID1A (AT-rich interaction domain 1A) • BRCA (Breast cancer early onset)
    |
    ARID1A mutation • BRCA mutation
    |
    NXP800
    over1year
    NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    NXP800
    over1year
    Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> May 2024
    Enrollment open • Trial initiation date
    |
    Venclexta (venetoclax) • azacitidine • HC-7366
    over1year
    NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Mayo Clinic
    New P1 trial • Metastases
    |
    NXP800
    over1year
    Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center | N=58 --> 18
    Enrollment change
    |
    Venclexta (venetoclax) • azacitidine • HC-7366
    over1year
    A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=80, Recruiting, HiberCell, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    VHL (von Hippel-Lindau tumor suppressor)
    |
    VHL mutation
    |
    Welireg (belzutifan) • HC-7366